Defunct Company
Total Trials
2
As Lead Sponsor
1
As Collaborator
Total Enrollment
89
NCT04373395
Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase: N/A
Role: Collaborator
Start: Jan 1, 2020
Completion: Dec 31, 2023
NCT05759234
A Study of HS248 in Patients With Advanced Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 15, 2022